Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06137118 · ClinicalTrials.gov registry record · Phase 1

AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia

A Phase 1 study of B-cell Acute Lymphoblastic Leukemia (B-ALL), sponsored by AstraZeneca.

Recruiting
Registry status
Phase 1
Development phase
163
Enrollment target
20
Study locations

NCT06137118 is a Phase 1 study of B-cell Acute Lymphoblastic Leukemia (B-ALL) that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 163 participants, above the 106-participant average among 6 other B-cell Acute Lymphoblastic Leukemia (B-ALL) trials with a reported enrollment target (54% higher). The trial reports 20 study locations across 13 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06137118, a Phase 1 study of B-cell Acute Lymphoblastic Leukemia (B-ALL), is actively recruiting participants, sponsored by AstraZeneca.

RECRUITING
Registry status
Phase 1
Development phase
163 participants
Enrollment target
20
Study locations

Study Summary

This is a Phase 1/2, global multicentre, open-label, single-arm, dose escalation and dose optimisation study of AZD0486 to evaluate the safety, tolerability, and efficacy of AZD0486 monotherapy in participants with R/R B ALL who have received ≥ 2 prior lines of therapies. The study will consist of 3 parts. Part A monotherapy dose escalation. Part B dose optimisation. Part C Dose expansion at the recommended phase 2 dose (RP2D)

Conditions Studied

B-cell Acute Lymphoblastic Leukemia (B-ALL)

Interventions

  • DRUG AZD0486

Study Locations (20)

Other

  • Research Site - Melbourne
  • Research Site - Porto Alegre
  • Research Site - São Paulo
  • Research Site - São Paulo
  • Research Site - Changsha

California

  • Research Site - Duarte
  • Research Site - Los Angeles
  • Research Site - Palo Alto

Quebec

  • Research Site - Montreal
  • Research Site - Montreal

Alabama

  • Research Site - Birmingham

Florida

  • Research Site - Tampa

Georgia

  • Research Site - Atlanta

Illinois

  • Research Site - Chicago

New York

  • Research Site - New York

Trial Details

FieldValue
Enrollment Target 163 participants
Start Date 2023-12-29
Est. Completion 2027-06-29
Phase Phase 1

Sponsor

AstraZeneca

1,285 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06137118

The ClinicalTrials.gov registry entry for NCT06137118 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 163 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 106-participant average among 6 other B-cell Acute Lymphoblastic Leukemia (B-ALL) trials with a reported enrollment target (54% higher). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with B-cell Acute Lymphoblastic Leukemia (B-ALL) appearing as the primary indexed condition, and to 1 intervention - of which AZD0486 is the first listed.

NCT06137118 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Other, California, Quebec.

Frequently Asked Questions

What is clinical trial NCT06137118 about?

NCT06137118 is a clinical study titled "AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia". This is a Phase 1/2, global multicentre, open-label, single-arm, dose escalation and dose optimisation study of AZD0486 to evaluate the safety, tolerability, and efficacy of AZD0486 monotherapy in participants with R/R B ALL who have received ≥ 2 prior lines of therapies. The study will consist of 3...

What is the current status of trial NCT06137118?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 163 participants. The study started on 2023-12-29. Estimated completion is 2027-06-29.

What conditions does trial NCT06137118 study?

This clinical trial studies the following conditions: B-cell Acute Lymphoblastic Leukemia (B-ALL).

What interventions are being tested in trial NCT06137118?

The interventions under investigation include: AZD0486 (DRUG).

Who is sponsoring clinical trial NCT06137118?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06137118 being conducted?

This trial has 20 study locations across Alabama, California, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for B-cell Acute Lymphoblastic Leukemia (B-ALL)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

B-cell Acute Lymphoblastic Leukemia (B-ALL)

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.